137 related articles for article (PubMed ID: 36811251)
21. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study.
Hatanaka T; Kakizaki S; Saito N; Nakano Y; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Kashiwabara K; Yoshinaga T; Tojima H; Naganuma A; Uraoka T
Intern Med; 2021 Jul; 60(14):2167-2174. PubMed ID: 33612679
[TBL] [Abstract][Full Text] [Related]
22. Detection of Non-Alcoholic Fatty Liver Disease with Non-invasive Tools in Turkish People Living with HIV and with Apparently Normal Liver Function.
Başaran NÇ; İdilman İ; Tokuçoğlu HA; Onur MR; Sönmezer MÇ; Özışık L; Karçaaltıncaba M; İnkaya AÇ; Ünal S
Curr HIV Res; 2023; 21(3):192-201. PubMed ID: 37455457
[TBL] [Abstract][Full Text] [Related]
23. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
[TBL] [Abstract][Full Text] [Related]
24. The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
Allen AM; Shah VH; Therneau TM; Venkatesh SK; Mounajjed T; Larson JJ; Mara KC; Schulte PJ; Kellogg TA; Kendrick ML; McKenzie TJ; Greiner SM; Li J; Glaser KJ; Wells ML; Chen J; Ehman RL; Yin M
Hepatology; 2020 Feb; 71(2):510-521. PubMed ID: 30582669
[TBL] [Abstract][Full Text] [Related]
25. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
[TBL] [Abstract][Full Text] [Related]
26. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
27. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
Morishita A; Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Tani J; Shi T; Himoto T; Tatsuta M; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Ono M; Masaki T
Hepatol Int; 2023 Jun; 17(3):606-614. PubMed ID: 36583842
[TBL] [Abstract][Full Text] [Related]
28. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
[TBL] [Abstract][Full Text] [Related]
29. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Idilman IS; Keskin O; Elhan AH; Idilman R; Karcaaltincaba M
Scand J Gastroenterol; 2014 May; 49(5):617-24. PubMed ID: 24694249
[TBL] [Abstract][Full Text] [Related]
30. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.
Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
Clin Exp Hepatol; 2022 Dec; 8(4):278-283. PubMed ID: 36683866
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
[TBL] [Abstract][Full Text] [Related]
32. Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C).
Mamidipalli A; Fowler KJ; Hamilton G; Wolfson T; Covarrubias Y; Tran C; Fazeli S; Wiens CN; McMillan A; Artz NS; Funk LM; Campos GM; Greenberg JA; Gamst A; Middleton MS; Schwimmer JB; Reeder SB; Sirlin CB
Eur Radiol; 2020 Sep; 30(9):5120-5129. PubMed ID: 32318847
[TBL] [Abstract][Full Text] [Related]
33. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.
Noureddin M; Lam J; Peterson MR; Middleton M; Hamilton G; Le TA; Bettencourt R; Changchien C; Brenner DA; Sirlin C; Loomba R
Hepatology; 2013 Dec; 58(6):1930-40. PubMed ID: 23696515
[TBL] [Abstract][Full Text] [Related]
34. Liver stiffness accuracy by magnetic resonance elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort.
Lara Romero C; Liang JX; Fernández Lizaranzazu I; Ampuero Herrojo J; Castell J; Del Prado Alba C; Domínguez Pascual I; Romero Gómez M
Rev Esp Enferm Dig; 2023 Apr; 115(4):162-167. PubMed ID: 35791792
[TBL] [Abstract][Full Text] [Related]
35. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.
Lemoine M; Assoumou L; Girard PM; Valantin MA; Katlama C; De Wit S; Campa P; Rougier H; Meynard JL; Necsoi C; Huefner AD; Van Luzen J; Schulze Zur Wiesch J; Bastard JP; Fellahi S; Mauss S; Stankov MV; Baumgarten A; Post G; Serfaty L; Ratziu V; Menu Y; Schlue J; Bedossa P; Capeau J; Costagliola D; Behrens G; Ingiliz P;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):713-722.e3. PubMed ID: 35436624
[TBL] [Abstract][Full Text] [Related]
36. Quantification of Liver Fat by MRI-PDFF Imaging in Patients with Suspected Non-alcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome, Liver Function Test and Ultrasonography.
Rodge GA; Goenka MK; Goenka U; Afzalpurkar S; Shah BB
J Clin Exp Hepatol; 2021; 11(5):586-591. PubMed ID: 34511820
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.
Middleton MS; Van Natta ML; Heba ER; Alazraki A; Trout AT; Masand P; Brunt EM; Kleiner DE; Doo E; Tonascia J; Lavine JE; Shen W; Hamilton G; Schwimmer JB; Sirlin CB;
Hepatology; 2018 Mar; 67(3):858-872. PubMed ID: 29028128
[TBL] [Abstract][Full Text] [Related]
38. The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food.
Yang Y; Xu K; Chen X; Ding J; Shi J; Li J
Magn Reson Med Sci; 2023 Apr; 22(2):263-271. PubMed ID: 35676065
[TBL] [Abstract][Full Text] [Related]
39. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
[TBL] [Abstract][Full Text] [Related]
40. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
